

# Life Science Industry in Austria

Advancing life science at the heart of Europe

Johannes Sarx, Austria Wirtschaftsservice  
*Tel Aviv, 7 September 2015*



# Agenda



- › Life Sciences in Austria – Fields of Excellence
  - › Therapeutics
  - › Medical Technology
  - › Production and Platform Technologies
  - › Advanced Diagnostics and Analytics
  - › Basic Research
- › The Austrian Life Sciences in Figures
- › Life Science Opportunities in Austria

# Life Sciences in Austria

## Fields of Excellence



# Life Sciences in Austria

## *Fields of Excellence*



Austrian life science companies and research organizations are renowned for their innovations in the following fields:

### > Therapeutics

Cancer: the major medical challenge in Europe today  
Infectious diseases: vaccines and anti-infectives

### > Medical technology

Keeping a step ahead with Austrian components  
Surveying the device innovators

### > Production and Platform Technologies

Better, faster, cheaper

### > Advanced Analytics and Diagnostics

The diagnostic value chain





# Therapeutics *Challenge Cancer*



- › Austria is at the forefront in the fight against cancer in Europe and plays a leading part in the worldwide campaign with several pioneering initiatives.
- › Be it innovative immunotherapy, novel molecular targets or radiation therapy, researchers and oncologists throughout Austria are working to develop and commercialize diagnostics and treatments.



AOP ORPHAN  
FOCUS ON RARE DISEASES



COMPREHENSIVE  
CANCER  
CENTER VIENNA



ONCOLAB  
Diagnosics GmbH - solutions for personalized medicine



oncotyrol  
Center for Personalized Cancer Medicine

SANOCHEMIA  
Pharmazeutika AG  
The Specialty Pharma Company



ViraTherapeutics



## Therapeutics

***Leading the fight against global pandemics and local infections / Vaccines***



- Offering solutions to combat the increasing worldwide spread of dangerous pathogens, a number of highly innovative Austrian companies are transforming the world of antibiotic therapy or working on novel vaccines and therapeutics, including those that deal with the threat of pandemic flu and other infectious diseases.





## Therapeutics *Other fields (among others)*



- › Respiratory Diseases:



- › Allergies:



- › Regenerative Medicine:



- › Other:





# Medical Technology: *Keeping a step ahead with Austrian components*



- › Medical devices and related technologies have always been a strong part of the life science industries in Austria.
- › From large international device companies, individual businesses with a single device and multiple companies supplying parts and know-how, Austrian industry embraces every stage in the value chain.





# Production and Platform Technologies

## *Better, faster, cheaper*



- › Austria has a wide variety of companies providing enabling technologies across the whole value chain of production processes.
- › Close cooperation between universities, research centres and industry as well as highly trained and experienced local scientists, experts and technicians ensure the highest quality of products and services.



Miti Biosystems  
Polycyclic Peptides Unlimited





# Advanced Diagnostics and Analytics

## *The diagnostic value chain*



- › Austria has been at the forefront of developments in the diagnostics sector, from the discovery of biomarkers through to the manufacture of equipment for IVD diagnostics and the actual handling of specimens for analysis.
- › Right down the value chain, Austria is innovating in diagnostics and it is the interplay between Austrian companies and some of the leading global diagnostic companies that gives Austria such a pivotal position in this industry.

**B BRAUN**  
SHARING EXPERTISE

**beSurence**  
... good to be sure

**BIOCRATES**  
LIFE SCIENCES

  
**greiner bio-one**

  
**IONIMED**  
ANALYTIK



**kiweno**

**LEXOGEN**

  
**PLATOMICS**

  
**VASEMA**



# Basic Research

## *Universities and applied research infrastructure*



- › 17 universities, 13 universities of applied sciences and 25 non-university research institutes provide the basis of Austria's life science innovations



universität  
wien

UNIVERSITÄT  
SALZBURG

vetmeduni  
vienna



TU  
Graz

TU  
WIEN



Ce-M-M-  
Research Center for Molecular Medicine  
of the Austrian Academy of Sciences

GMI  
GREGOR MENDEL INSTITUTE  
OF MOLECULAR PLANT BIOLOGY

IMBA  
Institute of Molecular Biotechnology  
of the Austrian Academy of Sciences

IMP  
Research Institute of Molecular Pathology

IST AUSTRIA  
Institute of Science and Technology

mfpl  
Molecular Function Laboratory



acib  
Austrian centre of  
Industrial Biotechnology

BioBank  
GRAZ

bioenergy 2020+

JOANNEUM  
RESEARCH

oncytrol  
Center for Personalized Cancer Medicine

WINGS4  
INNOVATION  
THE FUTURE OF LIFE SCIENCE RESEARCH

# The Austrian Life Sciences in Figures



# Austrian Life Sciences 2012

## Facts and Figures



723  
companies

50,180  
employees

17.73  
bn. EUR  
Turnover




Turnover  
equals about  
**5.4%**  
of the gross  
domestic  
product





# Austrian Life Sciences 2012

## Facts and Figures





# Austrian Dedicated Biotechnology Sector *Facts and Figures*



- › In 2012, there were 95 companies occupied wholly with biotechnology. This is a marked increase (+23%) compared to 2010.
- › The average dedicated bio-tech company is just eight years old.






# Austrian Dedicated Biotechnology Sector *Clinical Pipeline*



- › In 2012 there were 92 compounds in clinical development.
- › Compared to 2010, the pipeline has grown by 12 compounds (+15%).
- › 63 of the substances are biopharmaceutical drug candidates.
- › The majority of drug candidates are in the preclinical phase.
- › 22 biotherapeutic agents and 4 small molecules have reached the more advanced stages of drug development and are being tested in humans.



# Life Science Opportunities in Austria

[www.LifeScienceAustria.at](http://www.LifeScienceAustria.at)



## Examples of recent life science deals in Austria



### dutalys

Aquired by Hoffmann-La Roche/MS-Deal  
**488 m. USD**  
(12/2014)

### Savira

License deal with Roche  
**240 m. EUR**  
(05/2012)

### Apeiron

Strategic collaboration with Sanofi and Evotec  
**>200 m. EUR**  
(08/2015)

### Nabriva

VC investment  
**120 m. USD**  
(04/2015)

### Hookipa

VC investment  
**27.5 m. USD**  
(11/2013)

### Arsanis

VC investment  
**20 m. USD**  
(09/2013)

### Themis

VC investment  
**10 m. EUR**  
(05/2015)

### Haplogen Genomics


Acquired by Horizon  
**7.7 m. EUR**  
(01/2015)

On top of these deals, a large number of VC firms and corporate ventures invest in Austrian life science companies



# Life Sciences in Austria

## *Austria – the place to do business*





# Life Science Opportunities in Austria



- › Equity investment in innovative Biotech-/Medtech-start-ups
  - › Business Angel, VC, Corporate Venture
  - › Portfolio of 40-50 companies
- › In-licensing of Austrian technology to Israel market
- › Distribution/sales partner for Austrian company in Israel
- › Using Austria as regional headquarter for European operations
- › Creating a life science start-up in Austria
  - › aws (Grants, Loans, Equity, Fund of Fund)
  - › FFG (Grants, Loans)
  - › Regional Funding Agencies
- › Research partnership (applied or basic research)



# Life Science Austria

Advancing Austrian life science at the heart of Europe

Meet us@ CPhI Madrid 2015, BioEurope Munich 2015, Medica Düsseldorf 2015, Arab Health Dubai 2016, Health IT Conference 2016 Las Vegas, BioEurope Stockholm 2016, BIO San Francisco 2016...and anytime in Austria!

**Find out more:**

Johannes Sarx  
j.sarx@awsg.at

[www.lifescienceaustria.at](http://www.lifescienceaustria.at)